The study of more than two million veterans with diabetes details GLP-1 RA use relating to 175 outcomes; without ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the ...

Adults with type 2 diabetes using a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those using a ...

Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders.

People who take weight-loss drugs based on GLP-1 receptor agonists seem to have reduced risk for a litany of diseases, ...

Of over 350,000 adults with type 2 diabetes, thyroid cancer risk was significantly higher within the first year after GLP-1 agonist initiation compared with SGLT2 inhibitors, DPP-4 inhibitors ...

Learn how diabetes medications could revolutionize stroke prevention and enhance heart and brain health with breakthrough ...

Computational research conducted by scientists from Washington University in St. Louis shows that GLP-1 agonists can have ...

Insights from a study on GLP-1 receptor agonists reveal benefits for cardiometabolic health, with notable risks for ...

Adults with type 2 diabetes using a GLP-1 drug have a similar risk for thyroid cancer as those using other diabetes drugs, though increased thyroid cancer risk was observed in the first year after GLP ...

and SGLT2 inhibitors (536,068 people), as well as a control group that continued use of non-GLP-1 RA antihyperglycemics (usual care; 1,203,097 individuals). The associations of GLP-1 RA use with ...